Debbie Goldschmidt
Education
Ph.D., economics, Boston University; M.A., economics, Universitat Pompeu Fabra; B.A., mathematics, University of Pennsylvania
Summary of Experience
Dr. Goldschmidt is an economist who specializes in the application of statistics and econometrics to health economics and outcomes research (HEOR). Her work includes medical chart reviews, retrospective claims analyses, physician surveys, surveys of the general public, and clinical trial analyses. Dr. Goldschmidt has conducted research in a range of disease areas, including oncology, neurology, and immunology. Her research has been published in peer-reviewed journals and presented at clinical and health economics research conferences. Prior to joining Analysis Group, Dr. Goldschmidt worked at two financial services firms.
-
Real-world use and clinical impact of an electronic patient-reported outcome tool in patients with solid tumors treated with immuno-oncology therapy
Journal of Patient-Reported Outcomes, 2024
2024Dickson NR, Beauchamp KD, Perry TS, Roush A, Goldschmidt D, Edwards ML, Blakely LJ
-
Impact of Tardive Dyskinesia on Physical, Psychological, Social, and Professional Domains of Patient Lives: A Survey of Patients in the United States
Journal of Clinical Psychiatry, 2023
2023Jain R, Ayyagari R, Goldschmidt D, Zhou M, Finkbeiner S, Leo S
-
Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study
Therapeutic Advances in Hematology, 2023
2023Oladapo A, Kolodny S, Vredenburg M, Swallow E, Goldschmidt D, Sarathy K, Lopez P, Maitland H, Yee J
-
Impact of tardive dyskinesia on patients and caregivers: a survey of caregivers in the United States
Journal of Patient-reported Outcomes, 2023
2023Jain R, Ayyagari R, Goldschmidt D, Zhou M, Finkbeiner S, Leo S
-
Kidney Failure Attributed to Immunoglobulin A Nephropathy: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden
Kidney Medicine, 2023
2023Bensink ME, Goldschmidt D, Zhou ZY, Wang K, Lieblich R, Bunke MC
-
Direct health care costs associated with COVID-19 in the United States
Journal of Managed Care & Specialty Pharmacy, 2022
2022DeMartino J, Swallow E, Goldschmidt D, Yang K, Viola M, Radtke T, Kirson N
-
Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial
Arthritis Research & Therapy, 2022
2022Bergman M, Tundia N, Martin N, Suboticki JL, Patel J, Goldschmidt D, Song Y, Wright GC
-
Impact of clinical pathways on treatment patterns and outcomes for patients with non-small-cell lung cancer: real-world evidence from a community oncology practice
Journal of Comparative Effectiveness Research, 2022
2022Dickson NR, Beauchamp KD, Perry TS, Roush A, Goldschmidt D, Edwards ML, Blakely LJ
-
Defining Utility Values for Chorea Health States in Patients with Huntington's Disease
Advances in Therapy, 2022
2022Claassen DO, Ayyagari R, Goldschmidt D, Zhou M, Leo S, Ribalov R
-
Defining utility values for patients with tardive dyskinesia
Current Medical Research and Opinion, 2022
2022Ayyagari R, Goldschmidt D, Zhou M, Ribalov R, Caroff SN, Leo S
-
Burden of illness for patients with cholangiocarcinoma in the United States: a retrospective claims analysis
Journal of Gastrointestinal Oncology, 2021
2021Chamberlain CX, Faust E, Goldschmidt D, Webster N, Boscoe AN, Macaulay D, Linton Peters ML
-
Higher Medication Adherence and Lower Opioid Use Among Individuals with Autoimmune Disease Enrolled in an Adalimumab Patient Support Program in the United States
Rheumatology and Therapy, 2021
2021Fendrick AM, Macaulay D, Goldschmidt D, Liu H, Brixner D, Ali T, Mittal M
-
Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY
Rheumatology, 2020
2020Strand V, Tundia N, Wells A, Buch MH, Radominski SC, Camp HS, Friedman A, Suboticki JL, Dunlap K, Goldschmidt D, Bergman M
-
Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
Arthritis Research & Therapy, 2019
2019Strand V, Pope J, Tundia N, Friedman A, Camp HS, Pangan A, Ganguli A, Fuldeore M, Goldschmidt D, Schiff M
-
Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer
Advances in Therapy. 2018 Aug;35(8):1251-1264
2018Guérin A, Goldschmidt D, Small T, Gagnon-Sanschagrin P, Romdhani H, Gauthier G, Kelkar S, Wu EQ, Niravath P, Dalal AA
-
Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study
Advances in Therapy. 26 Mar 2018:1-12
2018Goldschmidt D, Dalal AA, Romdhani H, Kelkar S, Guerin A, Gauthier G, Wu EQ, Niravath P, Small T
-
December 4, 2024
-
February 26, 2024
-
December 1, 2023
-
June 27, 2023
-
March 3, 2023
-
February 13, 2023
-
July 11, 2022
-
June 4, 2021